NEW YORK--(BUSINESS WIRE)--Celmatix Inc., the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Adrienne Day has joined the company’s advisory board. Dr. Day joins as the company eyes upcoming nonclinical studies for the lead RSTK agonist program, and continued partnering interest in its category-defining multi-omic ovarian health platform. She will play a key role in supporting the strategic and scientific prioritization of new partnerships and programs as the company continues to expand its pipeline.
Dr. Day has more than 30 years of business development experience in the biotechnology and biopharmaceutical industries. She was most recently Senior Director of Business Development for Ferring Pharmaceuticals, where she launched technology access and research collaborations, identified and championed the acquisition of microbiome replacement therapy, and managed global academic collaborations with more than 60 academic institutions. Prior to her role at Ferring, Dr. Day ran consulting practice providing transaction and strategic support to venture capital, biotechnology, and biopharmaceutical organizations. She has previously served as Vice President of Business Development at what is now the Sanford Burnham Prebys Medical Discovery Institute, Vice President of Business Development at Conforma Therapeutics, Senior Director of Business Development at Molecumetics Ltd., and Associate Director of Corporate Development at Ligand Pharmaceuticals.
Dr. Piraye Yurttas Beim, Celmatix Founder and CEO commented, “Dr. Day is an incredible addition to our Strategic Advisory Board. Her experience with early-stage transactions and preclinical program management in women’s health will play an important role in our portfolio planning and pipeline as our lead program approaches the clinic. It is wonderful to have someone with Dr. Day’s breadth and depth of experience - from both a business and scientific perspective- to join us at this exciting moment for Celmatix.”
Dr. Day commented, “I am delighted to be joining Celmatix’s Advisory Board. In my career, I have been a strong advocate for innovation in women’s health R&D. The work that Celmatix is doing in ovarian health is a paradigm change for this important therapeutic area, and has the potential to improve the lives of millions of women worldwide. I look forward to working with them to champion the next generation of therapies through both internal development and partnering strategies.”
Dr. Day received her B.Sc., B.Sc. Honors, and Ph.D. degrees in Biochemistry from the University of Adelaide, Australia. She completed her postdoctoral training at the University of Southern California and the La Jolla Cancer Research Center.
Celmatix has previously announced collaborations with marquee partners including Evotec, Bayer, and The Bill and Melinda Gates Foundation.
About Celmatix
Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” RSTK program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health. Celmatix’s proprietary multi-omic ovarian health platform, the world’s largest of its kind, is the foundation of the company’s novel pipeline of first-in-class therapies. For more information, visit the company’s website at www.celmatix.com.
